PRESS RELEASE : Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

DGAP-News: Immunic, Inc. / Key word(s): Personnel 
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel 
2021-06-01 / 12:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel 
NEW YORK, June 1, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline 
of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the 
appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for 
legal and compliance matters and will become part of the management team of Immunic. 
"Inderpal is a seasoned legal executive, having spent 20 years in-house, advising several of the world's largest life 
sciences companies. As such, he brings to Immunic extensive legal knowledge related to clinical development, 
operations, regulatory affairs, and commercialization," stated Daniel Vitt, Ph.D., Chief Executive Officer and 
President of Immunic. "We welcome Inderpal to the management team and look forward to his guidance as we continue to 
advance our pipeline of selective oral immunology therapies, including our lead program, IMU-838, through clinical 
development and eventually to potential regulatory approval." 
Mr. Singh joins Immunic from Sandoz International GmbH, where he served as the Global Legal Head of Biopharma since 
January 2018. During his tenure at Sandoz and as a member of various leadership teams, he was responsible for all legal 
activities, including development, regulatory, and medical matters, as well as commercial operations, business 
development, alliance management and market access for biopharma. Before that, from 2015 through 2017, Mr. Singh served 
at Merck KGaA as Global Legal Head of Global Manufacturing and Supply and Regional Counsel of Middle East and Africa, 
Commonwealth of Independent States and Turkey. From 2013 to 2015, he was Legal Director (Europe) at Biogen Idec 
International GmbH. Earlier in his career, Mr. Singh spent 15 years in legal positions of increasing responsibility at 
Pfizer Deutschland GmbH and Pfizer Inc. (U.S.). 
After earning his college degree in India, Mr. Singh qualified as an attorney with specialization in Corporate and 
Commercial Law at Johannes-Gutenberg University in Mainz, Germany. He also completed two executive MBA programs at the 
University of Mannheim, Germany and INSEAD Business School in Fontainebleau, France. 
About Immunic, Inc. 
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology 
therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small 
molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular 
metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is 
currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and 
primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?t, is targeted for 
development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier 
function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please 
visit: www.imux.com. 
Cautionary Statement Regarding Forward-Looking Statements 
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes 
of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than 
statements of historical facts, included in this press release regarding strategy, future operations, future financial 
position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking 
statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three 
development programs and the targeted diseases; the potential for Immunic's development programs to safely and 
effectively target diseases; the nature, strategy and focus of the company and further updates with respect thereto; 
the development and commercial potential of any product candidates of the company; expectations regarding the 
capitalization, resources and ownership structure of the company; and the executive and board structure of the company. 
Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed 
in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such 
statements are based on management's current expectations and involve risks and uncertainties. Actual results and 
performance could differ materially from those projected in the forward-looking statements as a result of many factors, 
including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project 
future cash utilization and reserves needed for contingent future liabilities and business operations, the availability 
of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier 
studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity 
provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process 
and the impact of competitive products and technological changes. A further list and descriptions of these risks, 
uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on 
Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company's 
subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at 
www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date 
of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect 
events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in 
respect to actions taken or not taken based on any or all the contents of this press release. 
Contact Information 
Immunic, Inc. 
Jessica Breu 
Head of Investor Relations and Communications 
[phone] 
[e-mail] 
US IR Contact 
Rx Communications Group 
Paula Schwartz 
[phone] 
[e-mail] 
US Media Contact 
KOGS Communication 
Edna Kaplan 
[phone] 
[e-mail] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-01 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1202820 2021-06-01

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1202820&application_name=news

(END) Dow Jones Newswires

June 01, 2021 06:30 ET (10:30 GMT)